Global Health Ventures, Inc. (GHLV.OB) announced this morning that it has completed its research on its second drug in development, Relax-B. With a primary focus on sublingual, or “under the tongue,” medications, the specialty pharmaceutical company is developing Relax-B for anxiety attacks.
Relax-B is the sublingual formulation of Propranolol, a non-selective beta blocker mainly used in the treatment of hypertension and the first successful beta blocker ever developed. Propranolol is available under many other names as well depending on dose and release rate and is very commonly prescribed in generic form as propranolol hydrochloride, as well as an AstraZeneca and Wyeth product under the trade names Inderal. This author actually takes it on as “as needed” basis to control atrial fibrillations.
Oral Propranolol is a very slow acting drug with approximately a two hour absorption rate. Through its proprietary sublingual technology, Global Health Ventures expedited the absorption formulation and then had a third party conduct side-by-side research of Relax-B and Propranolol to evaluate bioavailability and dissolution profile. Bioavailability, the fraction of an administered dose of unchanged drug that reaches the systemic circulation is one of the principal pharmacokinetic properties of drugs. Drugs that are administered intravenously are considered to have 100% bioavailability, but oral medications must pass through the digestive system before reaching the bloodstream. Drug delivery systems are an ongoing concern to develop methods of regulating bioavailability as oral treatments are generally considered the most favorable in patients. Dissolution is crucial in the formulation process of drug discovery that encompasses measuring the rate of the drug becoming solvent, which has a direct impact on the drug’s bioavailability.
The data from the recently completed study, which was conducted under USP (United States Pharmacopeia) protocol, showed that the new Global formulation was able to deliver the drug 500 percent faster/quicker in dissolution and bioavailability than the oral Propranolol. This information suggests that lower quantities of the drug can be used through the Global formulation to achieve quicker and more effective results.
Global Health Ventures is now planning to move forward with clinical production and has human clinical trials slated for next year. Additionally, the Company is working on developing a low dosage Relax-B to be used as an anti-anxiety therapy as well as for treatment of hypertension.
More information on Global Health Ventures and its pipeline of compounds can be found on the Company’s website at www.globalhealth3000.com.
Legal Notice / Disclaimer
This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. Andrew Klips (“the author”) has based this document on information obtained from sources he believes to be reliable, but which has not been independently verified; the author makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the author only and are subject to change without notice. The author assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, the author assumes no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information provided within this Report.
The author does not own shares of Global Health Ventures.
No comments:
Post a Comment